@article{68302d2424cb4106af4d38e80c0838b0,
title = "Pulmonary hypertension in the premature infant population: Analysis of echocardiographic findings and biomarkers",
abstract = "Objective: Extremely low gestational age neonates (ELGANs) are at risk for pulmonary hypertension (PH). We hypothesized that PH, defined by echocardiogram at 36 weeks gestational age (GA), would associate with respiratory morbidity, increased oxidant stress, and reduced nitric oxide production. Study Design: ELGANs in the Vanderbilt fraction of the Prematurity and Respiratory Outcomes Program (PROP) who had echocardiograms at 36 ± 1 weeks GA were studied. Echocardiogram features of PH were compared with clinical characteristics as well as markers of oxidant stress and components of the nitric oxide pathway. Biomarkers were obtained at enrollment (median day 3), 7, 14, and 28 days of life. Results: Sixty of 172 infants had an echocardiogram at 36 weeks; 11 had evidence of PH. Infants did not differ by PH status in regards to demographics, respiratory morbidity, or oxidant stress. However, odds of more severe PH were significantly higher in infants with higher nitric oxide metabolites (NOx) at enrollment and with a lower citrulline level at day 7. Conclusions: Respiratory morbidity may not always associate with PH at 36 weeks among ELGANs. However, components of nitric oxide metabolism are potential biologic markers of PH in need of further study.",
keywords = "biomarkers, bronchopulmonary dysplasia, pulmonary hypertension",
author = "O'Connor, {Michael G.} and Divya Suthar and Kimberly Vera and Slaughter, {James C.} and Maitre, {Natalie L.} and Steven Steele and Amy Beller and Fike, {Candice D.} and Aschner, {Judy L.} and Moore, {Paul E.} and Austin, {Eric D.}",
note = "Funding Information: PROP Scholar award, Grant number: NIH K23 HL 098743; PROP Award, Grant number: UO1 HL 101456; Clinical pharmacology training grant, Grant number: T32 GM07569 Funding Information: We would like to thank the other PROP investigators: Barbara Schmidt, data coordinating center, U01 HL 101794; Alan Jobe and Claire Chougnet, Cincinnati, U01 HL 101800; Aaron Hamvas and Tom Ferkol, Washington University, U01 HL 101465; Phil Ballard and Roberta Keller, UCSF, U01 HL 101798; Gloria Pryhuber, Rita Ryan, and Tom Mariani, Rochester-Buffalo, U01 HL 101813; Mike Cotten, Stephanie Davis, and Judy Voynow, Duke-Indiana, U01 HL 101702. In addition, we would also like to thank the families who participated in this study. This work was supported by PROP scholar award, NIH K23 HL 098743 (Austin), and UO1 HL 101456 (Aschner) as well as T32 GM07569 in clinical pharmacology (O'Connor). No author has any conflict of interest to report related to the data published in this manuscript. Funding Information: We would like to thank the other PROP investigators: Barbara Schmidt, data coordinating center, U01 HL 101794; Alan Jobe and Claire Chougnet, Cincinnati, U01 HL 101800; Aaron Hamvas and Tom Ferkol, Washington University, U01 HL 101465; Phil Ballard and Roberta Keller, UCSF, U01 HL 101798; Gloria Pryhuber, Rita Ryan, and Tom Mariani, Rochester-Buffalo, U01 HL 101813; Mike Cotten, Stephanie Davis, and Judy Voynow, Duke-Indiana, U01 HL 101702. In addition, we would also like to thank the families who participated in this study. This work was supported by PROP scholar award, NIH K23 HL 098743 (Austin), and UO1 HL 101456 (Aschner) as well as T32 GM07569 in clinical pharmacology (O'Connor). Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",
year = "2018",
month = mar,
doi = "10.1002/ppul.23913",
language = "English (US)",
volume = "53",
pages = "302--309",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "3",
}